Big IPOs in 2014: INC, PRA, Catalent and more. Which firms are next?
Recipharm CEO Thomas Eldered met Outsourcing-pharma.com months before IPO
In February, Swedish CMO Recipharm finally confirmed the speculation it was about to go public with a prospectus that positioned it as a mid-tier player among the top ten group of the world’s biggest third-party drugmakers.
Two months later the CMO was listed on the NASDAQOMX and told us the move was about being able to “participate in the changes and consolidation that is occurring in the industry.”
True to its word Recipharm has been on the acquisition trail since, buying Italian contractor Corvette in August and Portugal’s Lusomedicamenta in November.
